Skip to content

Clinical Observation and Study on the Correlation between Monocyte-Platelet Aggregates and Knee Osteoarthritis

Clinical Observation and Study on the Correlation between Monocyte-Platelet Aggregates and Knee Osteoarthritis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116146
Enrollment
Unknown
Registered
2026-01-06
Start date
2026-01-12
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Interventions

Healthy control group:None

Sponsors

The First Affiliated Hospital of Jinan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: Knee Osteoarthritis Case Group: 1. Age: 40-75 years (inclusive), no gender restriction. 2. Patients diagnosed with knee osteoarthritis according to the Chinese Orthopaedic Association, Orthopaedic Surgery Branch, Joint Surgery Group's "Chinese Guidelines for the Diagnosis and Treatment of Osteoarthritis (2018 Edition)" (diagnosis can be made if criterion 1 plus any 2 others are met): (1) Recurrent knee pain within the past month; (2) X-ray (standing or weight-bearing) showing joint space narrowing, subchondral bone sclerosis and/or cysts, or osteophyte formation at the joint margins; (3) Age >=50 years; (4) Morning stiffness <=30 minutes; (5) Crepitus during activity. 3. Based on imaging results (anteroposterior and lateral X-rays of the knee), the target knee joint is Kellgren-Lawrence grade II–III, with plans for total knee arthroplasty: Grade I: minimal osteophytes Grade II: definite osteophytes, may have slight joint space narrowing Grade III: moderate joint space narrowing Grade IV: severe joint space narrowing and subchondral bone sclerosis. 4. Voluntarily participate and sign informed consent. Healthy Control Group: 1. Age and gender roughly matched to the case group. 2. No history of knee pain or swelling, and physical examination is normal. 3. No history of autoimmune diseases, active infections, hematological diseases, or malignant tumors. 4. Voluntarily participate and sign informed consent.

Exclusion criteria

Exclusion criteria: Exclusion criteria of knee osteoarthritis group: 1.Other knee diseases that cause knee pain or movement disorders (bone joint tuberculosis, bone joint tumor, acute traumatic arthritis, pigmented villonodular synovitis, septic arthritis, rheumatoid arthritis, metabolic bone disease, psoriatic arthritis, gouty arthritis, symptomatic cartilage calcification, bone necrosis or active infection, etc.). 2.Severe structural abnormalities of the joint: those with deformity, disability or loss of function of the knee joint. 3.Complicated with systemic diseases: severe heart, liver and kidney failure, malignant tumor, hematological system disease, immune deficiency, tuberculosis, hemophilia, mental disease and other diseases. 4.Those who have a clear history of mental disorders, or have a history of psychotropic drug abuse and drug abuse. 5.Those with positive serum Virology (HBeAg, HCV antibody, HIV antibody, Treponema pallidum antibody). 6.The investigator believes that it is not suitable to enter this trial. Exclusion criteria of healthy control group: 1.Have a history of knee pain, swelling or abnormal physical examination. 2.Those with history of autoimmune diseases, active infections, hematological diseases and malignant tumors. 3.Complicated with systemic diseases: severe heart, liver and kidney failure, malignant tumor, hematological system disease, immune deficiency, tuberculosis, hemophilia, mental disease and other diseases. 4.Long term oral hormone or immunosuppressant. 5.Pregnant or lactating women, or those with positive blood pregnancy test at screening; 6.Those who have a clear history of mental disorders, or have a history of psychotropic drug abuse and drug abuse. 7.Those with positive serum Virology (HBeAg, HCV antibody, HIV antibody, Treponema pallidum antibody). 8. Individuals whom the researcher believes are unsuitable to participate in this trial.

Design outcomes

Primary

MeasureTime frame
Proportion of MPA in peripheral blood;

Secondary

MeasureTime frame
Fluorescence Intensity and Distribution Characteristics of Monocyte-Platelet Aggregates in Frozen Sections of Synovial Tissue;Changes in the concentration of inflammatory factors in the supernatant of primary synovial cells after co-culture with monocyte-platelet aggregates;

Countries

China

Contacts

Public ContactHuantian Zhang

The First Affiliated Hospital of Jinan University

zhanghuantian@jnu.edu.cn+86 138 0280 0152

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026